Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 7/20 | 0.60 |
| ▸ | CMA1 | P23946 | 8/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.49 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.49 |
| ▸ | XIAP | P98170 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 5/20 | 0.46 |
| ▸ | CTRC | Q99895 | 1/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7370083 | 0.90 | ACE (0.65) | ACECMA1TSHRF2PRSS1 | |
| SCHEMBL25384899 | 0.87 | ACE (0.61) | ACECMA1F2PRSS1ACE2 | |
| SCHEMBL25384895 | 0.87 | ACE (0.61) | ACECMA1F2PRSS1ACE2 | |
| SCHEMBL25384891 | 0.87 | ACE (0.61) | ACECMA1F2PRSS1ACE2 | |
| SCHEMBL3692085 | 0.86 | ACE (0.77) | ACECMA1F2PRSS1ACE2 | |
| SCHEMBL22409423 | 0.86 | ACE (0.77) | ACECMA1F2PRSS1ACE2 | |
| SCHEMBL8378100 | 0.86 | ACE (0.77) | ACECMA1F2PRSS1ACE2 | |
| SCHEMBL3692081 | 0.86 | ACE (0.77) | ACECMA1F2PRSS1ACE2 | |
| SCHEMBL5900836 | 0.86 | ACE (0.77) | ACECMA1F2PRSS1ACE2 | |
| SCHEMBL5900839 | 0.86 | ACE (0.77) | ACECMA1F2PRSS1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6774110-B2 | ANTITHROMBOTIC ACTIVITY AND HIGH ORAL BIOAVAILABILITY; E.G. N-AMINOSULFONYL-D-DIPHENYLALANYL-L-PROLYL-((4-AMIDINOPHENYL)METHYL)AMIDE | LG LIFE SCIENCES LTD. (KR) | 2004-08-10 | — | — | US | disclosed |
| US-20020169113-A1 | Orally available peptidic thrombin inhibitors | LG LIFE SCIENCES LTD. (KR) | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169113-A1 | Orally available peptidic thrombin inhibitors | F2, SERPINC1, TFPI | ACE 257/4885CMA1 972/4885TSHR 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.